What type of study is this?

Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer

View Full Paper

Ask AI

Bookmark

Authors

Phase III trial demonstrates low-dose tamoxifen reduces recurrence in non-invasive breast cancer, indicating safety is favorable.

Low-dose tamoxifen led to no significant differences in benign events compared to placebo after 10 years.
The most affected site in the study was the uterus, with 30 cases in each treatment arm—a critical finding for safety assessment.
This phase III trial involved 5 mg/day of tamoxifen for three years, assessing its effect on benign gynecological conditions.
Results suggest a safe profile for low-dose tamoxifen, reinforcing its potential in breast cancer prevention and management.

Carbone et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark